Weekly somatrogon noninferior to daily somatropin in paediatric GHD
Weekly injections of somatrogon result in similar height gains to daily somatropin treatment in children with growth hormone deficiency, show results of a 12-month phase 3 trial.
Weekly injections of somatrogon result in similar height gains to daily somatropin treatment in children with growth hormone deficiency, show results of a 12-month phase 3 trial.
An oral growth hormone secretagogue receptor agonist produces larger GH responses than standard stimulation tests in children with growth hormone deficiency, study findings suggest.
A study of Brazilian children with isolated SHOX haploinsufficency who were followed up until adult height has demonstrated a long-term benefit of recombinant human growth hormone therapy with or without puberty modulator treatment.
A 4-year-old girl is referred to the local paediatric endocrine unit with signs of pubertal development.
Children with growth hormone deficiency maintain their growth trajectories if they switch from a daily recombinant human growth hormone to weekly lonapegsomatropin, and the vast majority prefer the less frequent injections, show the results of the fliGHt trial.
Treatment with recombinant human growth hormone results in an increased final adult height in children with molecularly confirmed Silver–Russell syndrome, as well as an improved BMI that persists after treatment cessation, say researchers.
The benefit of initiating recombinant human growth hormone before puberty in patients with Noonan syndrome occurs regardless of whether the children carry a PTPN11 mutation, suggests research published in Endocrine Connections.
Recorded: Thursday 5 November, 2020
Professor Savage was joined by growth disorder and digital health specialists to address resistant factors to the adoption of technology.
Whole-gene deletion of MKRN3 can cause central precocious puberty without any features of Prader–Willi syndrome, researchers report.
An extensive multinational study of patients with disordered thyroid hormone transport due to MCT8 deficiency has identified key characteristics that could help early diagnosis and the treatment of underlying risk factors associated with a poor outcome in affected patients.